News & Publications

Dec 13, 2021

Foresight Diagnostics' PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas

Dec 13, 2021

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Dec 13, 2021

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Dec 13, 2021

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Dec 13, 2021

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Oct 12, 2021

Lightning does strike twice: leveraging phased variants to enhance minimal residual disease detection

icon-download Download Review Paper

Sep 20, 2021

What’s Next for Liquid Biopsy Tests?

Jul 26, 2021

Foresight Diagnostics Commercializing PhasED-seq Liquid Biopsy Tech for Improved MRD Detection

Jul 22, 2021

Foresight Diagnostics’ PhasED-Seq detects circulating tumor DNA at extremely low levels

Jul 22, 2021

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Jul 22, 2021

Foresight Diagnostics’ PhasED-Seq Circulating Tumor DNA Platform Demonstrates Highly Sensitive Minimal Residual Disease (MRD) Detection in B-Cell Lymphomas

Jun 17, 2021

Foresight Diagnostics to Present a Vision of the New Standard of Lymphoma MRD Detection at the 16th International Conference on Malignant Lymphoma

Jun 03, 2021

Phased variants improve DLBCL minimal residual disease detection at the end of therapy

Jun 03, 2021

Foresight Diagnostics to Present Clinical Data of Industry-Leading Minimal Residual Disease (MRD) Technology in Lymphoma and Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 03, 2021

Leveraging Phased Variants for Personalized Minimal Residual Disease Detection in Localized Non-Small Cell Lung Cancer

Jun 02, 2021

Foresight Diagnostics Completes Series A Financing to Accelerate Development of its Industry-Leading Minimal Residual Disease (MRD) Technology

Mar 25, 2020

Integrating genomic features for non-invasive early lung cancer detection

Nov 13, 2019

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Jul 25, 2019

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
2022-01-17 06:00